Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition

Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition

Secukinumab, a monoclonal antibody targeting interleukin-17A, is effective for treating moderate-to-severe plaque psoriasis but may induce paradoxical inflammatory bowel disease, particularly Crohn’s disease. We describe a 41-year-old male with a history of psoriasis who developed new-onset Crohn’s...

Full description

Saved in:
Bibliographic Details
Main Authors: Huiling Dai, Chenyi Xu, Yehuang Wang, Kunlan Wu, Yang Zhang, Hao Ge, Yanlan Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
psoriasis
secukinumab
perianal abscess
Crohn’s disease
drug-related adverse reactions
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1628461/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items